Use of mycophenolate mofetil in inflammatory bowel disease

作     者：Terrence Tan Ian Craig Lawrance 

作者机构：Department of GastroenterologyFremantle Hospital Centre for Inflammatory Bowel DiseasesFremantle Hospital Department of Medicine and PharmacologyUniversity of Western AustraliaFremantle Hospital 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2009年第15卷第13期

页      面：1594-1599页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Inflammatory bowel disease Mycophenolatemofetil Therapy Crohn's disease Ulcerative colitis 

摘      要：AIM:To assess the efficacy and safety of mycophenolate mofetil(MMF)prospectively in inflammatory bowel disease(IBD)patients intolerant or refractory to conventional medical ***:Crohn s disease(CD)or ulcerative colitis/ IBD unclassified(UC/IBDU)patients intolerant or refractory to conventional medical therapy received MMF(500-2000 mg bid).Clinical response was assessed by the Harvey Bradshaw index(HBI)or colitis activity index(CAI)after 2,6 and 12 mo of therapy,as were steroid usage and adverse ***:Fourteen patients(9 CD/5 UC/IBDU;8M/6F;mean age 50.4 years,range 28-67 years)were treated and prospectively assessed for their response to oral *** the 11 patients who were not in remission on commencing MMF,7/11(63.6%)achieved remission by 8 *** 3 patients in remission on commencing MMF maintained their *** patients were still on MMF at 6 mo with 9/14(64.3%)in remission,while of 12 patients followed for 12 mo,8 were in remission without dose escalation(66.7%).Three patients were withdrawn from the MMF due to drug *** were no serious adverse events attributed due to the ***:MMF demonstrated efficacy in the management of difficult *** appeared safe,well tolerated and efficacious for both short and long-term therapy,without the need for dose *** evaluation of MMF comparing it to conventional immunosuppressants is required.